Table II.
bcirg006 | ||||
---|---|---|---|---|
nsabpB31,ncctgN9831a | ac → th | tch | hera | |
Regimen | Concurrent | Concurrent | Sequential | |
Follow-up | 2 Years | 2 Years | 1 Year | |
Evaluable patients (n) | 3351 | 3222 | 3387 | |
Hazard ratios | ||||
dfs | 0.48
2p=3×10−12 |
0.49
p<0.0001 |
0.61
p=0.0002 |
0.54
p<0.0001 |
ddfs | 0.47
2p=8×10−10 |
NR | NR | 0.51
p<0.0001 |
os | 0.67
2p=0.015 |
NR | NR | 0.76
p=0.26 |
Combined analysis.
nsabp = National Surgical Adjuvant Breast and Bowel Project; ncctg = North Central Cancer Treatment Group; bcirg = Breast Cancer International Research Group; hera = Herceptin Adjuvant Trial; ac → th = doxorubicin–cyclophosphamide/docetaxel–trastuzumab; tch = docetaxel–carboplatin–trastuzumab; dfs = disease-free survival; ddfs = distant dfs; os = overall survival.